摘要
目的探讨哌拉西林/他唑巴坦治疗颅脑损伤合并肺部感染的临床效果和安全性。方法将60例颅脑损伤合并肺部感染的患者随机分为观察组和对照组各30例,观察组采用哌拉西林/他唑巴坦治疗,对照组使用头孢他啶,比较二者治疗的效果。结果观察组总有效率为93.33%,对照组为70.00%,两组比较差异有统计学意义(P<0.05);观察组患者抗感染时间为(9.1±0.5)d,对照组为(12.6±0.7)d,两组比较差异有统计学意义(P<0.05)。结论哌拉西林/他唑巴坦具有安全、高效、抗菌谱广的特点,是治疗颅脑损伤合并肺部感染的有效药物,值得临床推广应用。
OBJECTIVE To explore the clinical effects and safety of piperacillin and tazobactam on treating pulmonary infection due to brain injury.METHODS A total of 60 cases patient with pulmonary infection due to brain injury were randomly divided randomly into the investigation group(30 cases) and the control group(30 cases).The former took the piperacillin and tazobactam,the latter took the ceftazidime,the therapeutic effect was observed and compared.RESULTS In investigation group A,the total improving rate was 93.33%,while in control group,the improving rate was 70.00%.The difference was significant between both groups(P〈0.05).The infection duration of group investigation was(9.1±0.5)days,and control group was(12.6±0.7)days with significant difference(P〈0.05).CONCLUSION The pulmonary infection due to brain injury treated with piperacillin and tazobactam is safe,effective and broad spectrum antimicrobial,appearing to be an excellent drug,and hence is worthy of being recommended in clinical practice.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2011年第11期2320-2322,共3页
Chinese Journal of Nosocomiology